CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study.

about

Pharmacogenomics Guided-Personalization of Warfarin and Tamoxifen.Precision Medicine in Hormone Receptor-Positive Breast Cancer.

P2860

Q48125765-8D5987D5-1827-4FAC-98E6-8EA1A1D04105 Q55379220-70490D99-374D-43B2-9830-FF5B40AD451C

P2860

CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study.

Item

http://www.wikidata.org/entity/Q38668766

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

CYP2D6 genotype is not associa ...... from a population-based study.

@en

type

Item

label

CYP2D6 genotype is not associa ...... from a population-based study.

@en

prefLabel

CYP2D6 genotype is not associa ...... from a population-based study.

@en

P1476

CYP2D6 genotype is not associa ...... from a population-based study.

@en

P2093

C Chenault

http://www.w3.org/2001/XMLSchema#string

C K Osborne

http://www.w3.org/2001/XMLSchema#string

D L Hertz

http://www.w3.org/2001/XMLSchema#string

J M Rae

http://www.w3.org/2001/XMLSchema#string

R J Hartmaier

http://www.w3.org/2001/XMLSchema#string

S G Hilsenbeck

http://www.w3.org/2001/XMLSchema#string

S Oesterreich

http://www.w3.org/2001/XMLSchema#string

S Philips

http://www.w3.org/2001/XMLSchema#string

T C Skaar

http://www.w3.org/2001/XMLSchema#string

P2860

Pharmacogenomics knowledge for personalized medicine

Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline

Genotype-guided tamoxifen therapy: time to pause for reflection?

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype

Tamoxifen and CYP2D6: a contradiction of data.

Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients

CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.

Concordance of metabolic enzyme genotypes assayed from paraffin-embedded, formalin-fixed breast tumors and normal lymphatic tissue.

Effect of screening and adjuvant therapy on mortality from breast cancer.

P2888

s10549-017-4400-8

P304

277-287

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10549-017-4400-8

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

166

http://www.w3.org/2001/XMLSchema#string

P50

Kelley Kidwell

Matthew J Sikora

P577

2017-07-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1090832458

http://www.w3.org/2001/XMLSchema#string

P698

28730340

http://www.w3.org/2001/XMLSchema#string

P932

6028015

http://www.w3.org/2001/XMLSchema#string

CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study.

about

P2860

P2860

CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P6179

P698

P932